RxDoctor Payments Data

Scott Kolander, MD

Internal Medicine · Ewing, NJNPI 1942242748

Payments from drug & device makers

$759in general payments, 2019–2025

Across 48 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$161
  • Novo Nordisk$144
  • Merck$69
  • Exact Sciences$61
  • Lilly USA, LLC$58
  • GSK$45
  • plus $221 from 11 others

What the payments were for

  • Food & beverage$74798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$759 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$122,394
Medicare patients
287
Services billed
1,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban378$181,182
JardianceEmpagliflozin46$41,907
MyrbetriqMirabegron109$39,536
AtivanLorazepam12$32,398
JanuviaSitagliptin Phosphate25$26,838
OzempicSemaglutide15$25,987
ProliaDenosumab13$23,310
TradjentaLinagliptin22$20,728
XareltoRivaroxaban37$16,721
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$15,802
Breo ElliptaFluticasone/Vilanterol29$12,458
FarxigaDapagliflozin Propanediol21$11,195
SynthroidLevothyroxine Sodium64$8,572
BenicarOlmesartan Medoxomil21$7,509
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$6,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$181,182378 claims
Boehringer IngelheimJardiance, Tradjenta$13$62,63568 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$45$39,73695 claims
MerckJanuvia$69$26,83825 claims
Novo NordiskOzempic$144$25,98715 claims
AmgenProlia$15$23,31013 claims
AstraZenecaFarxiga, Nexium$44$17,40137 claims
Johnson & JohnsonXarelto$16$16,72137 claims
AbbVieSynthroid$16$8,57264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Ewing

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →